Migraine Sufferers can Rejoice: A Breakthrough Drug Erenumab to Half the Length of Suffering Time
Scientists have developed an antibody which blocks the neural brain pathway CGRP, in order to prevent attacks. It is the first lab-made antibody in 20 years to halve the length of time migraine sufferers have to endure. More on Erenumab…